구독하기
연구 모델
서비스
전임상 효능 평가
Resource
Chronic-PKD Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
Chronic-PKD Mouse
제품명
Chronic-PKD Mouse
제품 ID
C001974
품종 계통
C57BL/6Cya-Pkd1em1floxCdh16em1(IRES-MerCreMer)/Cya
Backgroud
C57BL/6Cya
상태
이 마우스 계통을 논문에서 사용할 경우, “Chronic-PKD Mouse (카탈로그 번호 C001974)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
Disease Animal Models
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
Disease Animal Models
기본 정보
검증 데이터
관련 자료
기본 정보
유전자명
유전자 별칭
PC1, mFLJ00285
NCBI ID
염색체
Chr 17
MGI ID
Datasheet
품종 계통 설명
Polycystin-1 (PC1), encoded by the PKD1 gene, is a large transmembrane glycoprotein that orchestrates critical cellular processes—including cell–cell and cell–matrix interactions, calcium signaling, and mechanosensation—in renal tubular epithelial cells. PC1 regulates various aspects of cellular function, including signal transduction, cytoskeletal remodeling, and cell adhesion. It forms a functional complex with Polycystin-2 (PC2), the product of the PKD2 gene, to maintain intracellular calcium homeostasis and facilitate mechanotransduction [1]. Disruption of PC1 signaling, due to PKD1 mutations—which account for approximately 85% of autosomal dominant polycystic kidney disease (ADPKD) cases—undermines these regulatory pathways, promoting abnormal cell proliferation and cyst formation [2]. Clinically, ADPKD is characterized by the progressive development of multiple fluid-filled cysts, renal enlargement, hypertension, and eventual progression to end-stage kidney disease (ESKD). With a global incidence estimated at 1 in 400 to 1 in 1000 individuals, ADPKD affects nearly 500,000 people in the United States alone and frequently involves extra-renal manifestations, including the heart, liver, pancreas, spleen, and arachnoid membrane [3]. Notably, genotypic heterogeneity exists, with PKD1 mutations often associated with an earlier onset and more aggressive disease course [2-3].
Traditional systemic Pkd1 knockout models are typically embryonically lethal, precluding long-term pathogenesis studies. In contrast, inducible, kidney-specific conditional knockout models using the Cre-LoxP system recapitulate the clinical features of human ADPKD and permit the investigation of disease progression in adult mice [4-5]. Chronic-PKD mice are an inducible conditional Pkd1 knockout model generated by crossing Pkd1-flox mice with kidney-specific, tamoxifen-inducible Cre mice (Cdh16-MerCreMer mice). Preliminary data show that palpable renal enlargement occurs at 6 weeks after tamoxifen induction. At 10 weeks post-induction, a polycystic kidney phenotype is visible upon dissection, with no mortality observed and a more pronounced phenotype in male mice. We will continue monitoring this model to characterize late-stage phenotypes and the overall disease progression.
Reference
Su Q, Hu F, Ge X, Lei J, Yu S, Wang T, Zhou Q, Mei C, Shi Y. Structure of the human PKD1-PKD2 complex. Science. 2018 Sep 7;361(6406):eaat9819.
Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009;60:321-37.
Mahboob M, Rout P, Leslie SW, et al. Autosomal Dominant Polycystic Kidney Disease. [Updated 2024 Mar 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
Sieben CJ, Harris PC. Experimental Models of Polycystic Kidney Disease: Applications and Therapeutic Testing. Kidney360. 2023 Aug 1;4(8):1155-1173.
Happé H, Peters DJ. Translational research in ADPKD: lessons from animal models. Nat Rev Nephrol. 2014 Oct;10(10):587-601.
변형 전략
Chronic PKD(inducible) was generated by crossing Pkd1‑flox mice with kidney‑specific, tamoxifen‑inducible Cre mice (Cdh16‑MerCreMer mice, catalog No.: C001432). For detailed information on Cdh16‑MerCreMer mice, please refer to the strain datasheet. The gene‑editing strategy for Pkd1‑flox mice is shown below.

Figure 1. Gene editing strategy for Pkd1-flox mice. Exons 2–8 of the mouse Pkd1 gene serve as the conditional knockout (cKO) region.
응용 분야
Research on renal tubular calcium homeostasis and mechanotransduction;
Research on renal tubular structure, function, and signal transduction;
Research on autosomal dominant polycystic kidney disease (ADPKD);
Research on other renal diseases.
검증 데이터
1. Experimental Protocol and Induction Regimen for Chronic Polycystic Kidney Disease
Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice were divided into three groups: Group 1 (G1) served as the corn oil vehicle control, while Group 2 (G2) and Group 3 (G3) were induced with Tamoxifen (TAM) at dosages of 100 mg/kg and 200 mg/kg, respectively. All mice received daily intraperitoneal (i.p.) injections for 5 consecutive days starting at approximately 3 weeks of age. Serum and urine samples were collected at weeks 2, 4, 6, 8, and 10 post-induction for biochemical analysis. The study was terminated at week 10, at which point kidneys were harvested and weighed for subsequent analysis, including the determination of kidney weight, kidney index, and histopathological examination.

Figure 2. Experimental schematic and induction regimen.
2. Renal Phenotype (Gross Appearance and Kidney Index)
Results indicated that kidney weight and organ index were significantly increased in male mice from the G2 (100 mg/kg TAM) and G3 (200 mg/kg TAM) groups compared to controls. In female mice, these parameters showed an increasing trend but did not reach statistical significance. (Bars represent Mean ± SD, Two-way ANOVA, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.)

Figure 3. Renal phenotype of Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice at 10 weeks post-Tamoxifen (TAM) induction (n=3~7).
(A) Gross appearance of kidneys from each group at 10 weeks post-induction.
(B) Quantitative analysis of renal effects 10 weeks after induction with 100 mg/kg and 200 mg/kg TAM, assessing left and right kidney weights and kidney index (percentage of total kidney weight to body weight).
3. Histopathological Observation
Results demonstrated that both G2 (100 mg/kg TAM) and G3 (200 mg/kg TAM) induction regimens successfully elicited a polycystic kidney phenotype in both male and female mice. Compared to the G1 (Corn Oil) group, the Cystic Index and Cyst Density were significantly elevated in both G2 and G3 groups. Notably, the G3 group exhibited higher values than G2, indicating a dose-dependent effect. Furthermore, males in the G3 group showed higher indices than females, suggesting that the dose-dependent response to TAM induction is more pronounced in male mice. (Bars represent Mean ± SD, Two-way ANOVA, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Figure 4. Renal pathology of Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice at 10 weeks post-Tamoxifen (TAM) induction (n=3~7).
(A) Representative H&E staining images of kidneys from each group at 10 weeks post-induction. Black arrows indicate renal cysts.
(B) Quantitative analysis of Cystic Index and Cyst Density at 10 weeks post-induction. Cystic Index: percentage of cystic area to total area (%); Cyst Density: number of cysts per unit renal area (NO./mm²).
Scale bars: 2 mm (low magnification); 200 μm (high magnification).
4. Body Weight and Biochemical Indicators
(1)Male
Throughout the study, body weight in all groups showed a steady increase; however, G2 (100 mg/kg TAM) and G3 (200 mg/kg TAM) males exhibited lower weights compared to the G1 (Corn Oil) group, suggesting an association between polycystic kidney progression and mild growth retardation. Over time, urine UACR, serum BUN, and serum CREA levels in G2 and G3 groups showed an upward trend relative to G1, with a more pronounced elevation observed in G3. At 10 weeks post-induction, urine UACR in G3 males was significantly elevated compared to G1, while serum BUN and CREA levels showed an increasing trend without statistical significance. Bars represent Mean ± SD, t-test, ns indicates no statistical significance (P>0.05), ****P<0.0001.

Figure 5. Monitoring of body weight, urinary, and serum biochemical parameters in Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice at 10 weeks post-Tamoxifen (TAM) induction (male, n=3).
(A) Growth curves of male mice in each group.
(B) Urinary albumin-to-creatinine ratio (UACR) at weeks 2, 4, 6, 8, and 10 post-TAM induction.
(C-D) Serum Blood Urea Nitrogen (BUN) levels (C) and Creatinine (CREA) levels (D) at weeks 2, 4, 6, 8, and 10 post-TAM induction.
(E) Comparison of urine UACR, serum BUN, and serum CREA levels between G1 (Corn Oil) and G3 (200 mg/kg TAM) males at 10 weeks post-induction.
(2)Female
Throughout the study, body weight in all female groups increased steadily with no significant differences, indicating that the progression of polycystic kidney disease did not impact somatic growth in females. Over time, urine UACR levels in G2 (100 mg/kg TAM) and G3 (200 mg/kg TAM) groups were elevated compared to the G1 (Corn Oil) group, whereas serum BUN and CREA levels remained comparable to controls. At 10 weeks post-induction, urine UACR in G3 females was significantly higher than in G1, while serum BUN and CREA levels showed no statistically significant difference. (Bars represent Mean ± SD, t test, ns indicates no statistical significance (P>0.05), *P<0.05.

Figure 6. Monitoring of body weight and renal function in Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice at 10 weeks post-Tamoxifen (TAM) induction (female, n=3).
(A) Growth curves of female mice in each group.
(B) Urinary albumin-to-creatinine ratio (UACR) at weeks 2, 4, 6, 8, and 10 post-TAM induction.
(C-D) Serum Blood Urea Nitrogen (BUN) levels (C) and Creatinine (CREA) levels (D) at weeks 2, 4, 6, 8, and 10 post-TAM induction.
(E) Comparison of urine UACR, serum BUN, and serum CREA levels between G1 (Corn Oil) and G3 (200 mg/kg TAM) females at 10 weeks post-induction.
5. Model Summary
In conclusion, Tamoxifen (TAM) induction successfully elicited a polycystic kidney phenotype in Pkd1flox/flox;Cdh16-MerCreMer[KI/KI] mice, with renal injury severity exhibiting a clear dose-dependent manner. Compared to the low-dose group (G2, 100 mg/kg), the high-dose group (G3, 200 mg/kg) displayed a more pronounced phenotype, characterized by significantly greater elevations in kidney weight, kidney index, cystic index, and cyst density. Furthermore, the G3 group showed more marked increases in urinary albumin-to-creatinine ratio (UACR) and a stronger upward trend in renal function markers (BUN, CREA) throughout the study.
Additionally, the model exhibited significant sexual dimorphism: male mice experienced mild growth retardation, whereas females maintained normal growth. The severity of cyst formation, renal impairment (UACR), and the dose-dependent response were all more pronounced in males than in females. Therefore, to establish a robust model with a stable and significant phenotype, we recommend inducing 3-week-old male Pkd1 conditional knockout mice with a 200 mg/kg dose of Tamoxifen.
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
